Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiuyuan Gene Engineering Files for China Approval of Ozempic Biosimilar

publication date: Apr 8, 2024

Hangzhou Jiuyuan Gene Engineering, along with its major shareholder, Huadong Medicine, has filed for approval of Jiyoutai, its biosimilar to Novo Nordisk’s Ozempic (semaglutide), a weight loss drug. Novo Nordisk holds patent rights to the drug in China until 2026. Ozempic was the world's best-selling diabetes drug last year, even though most of the sales came from people using the drug to lose weight. The active ingredient of the drug, semaglutide, is also used at a lower dose in Novo’s Wegovy, which targets weight loss. Jiyoutai could become the first approved China developed semaglutide biosimilar. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here